Experience with indole-3-carbinol used to treat diseases of the breast and to prevent breast cancer
Objective. The Russian and foreign experience with indole-3-carbinol, a substance with proven multitargeted antitumor activity, in the treatment of benign breast diseases and in the prevention of breast cancer was summarized. There are results of foreign experimental and clinical studies, and the randomized, double-blind, placebo-controlled trial of the efficacy of a drug based on indole-3-carbinol (Indinol forto) in treating cyclic mastalgia (mastodynia) and benign breast dysplasia (fibrocystic mastopathy), which was conducted in the Russian Federation in 2010–2013.Smetnik A.A., Smetnik V.P., Kiselev V.I.
Subjects and methods. This clinical trial included 62 patients aged 20 to 45 years. 30 patients received indole-3-carbinol 400 mg/day and 32 took placebo during 6 menstrual cycles. After 6 months of therapy, its efficiency was found to be, in terms of breast tenderness, significantly higher in the Indinol forto group than in the placebo group (83.3% vs 50.3%; p = 0.002). Following 6 months of treatment, breast tenderness reduced or disappeared in 83.0% of the patients in the mastopathy subgroup (in 47.0% in the placebo group; p = 0.004). The Indinol forto group also showed an increment in the plasma level of sex steroid-binding globulin and a statistically significant rise in the ratio of urinary estrogen metabolites (2-hydroxyestrone/16α-hydroxyestrone).
Results. The investigation provided evidence that the new multitargeted drug Indinol forto was effective in treating patients with cyclic mastalgia (mastodynia) and mastopathy. Considering that the known mechanisms of action of indole carbinol characterize it as an agent having a protective effect against cancer, this result is particularly important in the terms of the prevention of breast cancer in patients with cyclic mastalgia. The results of studies demonstrating the positive effect of indole-3-carbinol and 3,3’-diindolylmethane on the clinical markers of an increased risk for breast cancer (mastalgia, mastodynia, and other manifestations of fibrocystic breast disease) confirm the important role of these molecules as preventive strategies to reduce the risk of breast cancer.
Conclusion. These findings have led to the conclusion that Indinol forto may be recommended for the treatment of patients with both cyclic mastalgia (mastodynia) and mastopathy.
Keywords
indole-3-carbinol
estrogen metabolite
cyclical mastalgia
mastopathy
breast cancer
BRCA1
Supplementary Materials
- Fig. 1. The role of BRCA1 protein in the development of breast cancer
- Fig. 2. Dynamics of pain intensity relative to baseline
- Fig. 3. The dynamics of the ratio 2ONE1 / 16αONE1, the evaluation by the qualitative scale
References
1. Thomson C.A., Ho E., Strom M.B. Chemopreventive properties of 3,3’-diindolylmethane in breast cancer: evidence from experimental and human studies. Nutr. Rev. 2016; 74(7): 432-43.
2. Karikas G. Chemoprevention molecular and biochemical mechanisms involved in cancer control and management. Health Sci. J. 2011; 5(2): 149-56.
3. Wong G.Y., Bradlow L., Sepkovic D., Mehl S., Mailman J., Osborne M.P. Dose-ranging study of indole-3-carbinol for breast cancer prevention. J. Cell Biochem. Suppl. 1997; 28-29: 111-6.
4. Licznerska B., Baer-Dubowska W. Indole-3-carbinol and its role in chronic diseases. Adv. Exp. Med. Biol. 2016; 928: 131-54.
5. Haefele A., Word B., Yongmei X., Hammons G.J., Lyn-Cook B.D. Indole-3-carbinol (I3C) modulates expression of DNA methyltransferases 1, 3a, and 3b in pancreatic cancer cells: Effects of gender and a novel (C®T) polymorphism in the promoter region of DNMT 3b. Int. J. Cancer Prevention. 2007; 2: 245-55.
6. Beaver L.M., Yu T.W., Sokolowski E.I., Williams D.E., Dashwood R.H., Ho E. 3,3’-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells. Toxicol. Appl. Pharmacol. 2012; 263(3): 345-51.
7. Fuentes F., Paredes-Gonzalez X., Kong A.T. Dietary glucosinolates sulforaphane, phenethyl isothiocyanate, indole-3-carbinol/ 3,3’-diindolylmethane: anti-oxidative stress/ inflammation, nrf2, epigenetics/epigenomics and in vivo cancer chemopreventive efficacy. Curr. Pharmacol. Rep. 2015; 1(3): 179-96.
8. Terry P., Wolk A., Persson I., , Magnusson C. Brassica vegetables and breast cancer risk. JAMA. 2001; 285(23): 2975-7.
9. Van Poppel G., Verhoeven D.T., Verhagen H., Goldbohm R.A. Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv. Exp. Med. Biol. 1999; 472: 159-68.
10. Verhagen H., Poulsen H.E., Loft S., van Poppel G., Willems M.I., van Bladeren P.J. Reduction of oxidative DNA-damage in humans by brussels sprouts. Carcinogenesis. 1995; 16(4): 969-70.
11. Cohen J. H., Kristal A.R., Stanford J.L. Fruit and vegetable intakes and prostate cancer risk. J. Natl. Cancer Inst. 2000; 92: 61-8.
12. Anderton M.J., Manson M.M., Verschoyle R.D., Gescher A., Lamb J.H., Farmer P.B. et al. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice. Clin. Cancer Res. 2004; 10(15): 5233-41.
13. Wattenberg L.W., Loub W.D. Inhibition of polycyclic aromatic hydrocarbon-induced neoplasia by naturally occurring indoles. Cancer Res. 1978; 38: 1410-3.
14. Banerjee S., Kong D., Wang Z., Bao B., Hillman G.G., Sarkar F.H. Attenuation of multi-targeted proliferation linked signaling by 3,3’-diindolylmethane (DIM): from bench to clinic. Mutat. Res. 2011; 728(1-2): 47-66.
15. Loub W.D., Wattenberg L.W., Davis D.W. Aryl hydrocarbon hydroxylase induction in rat tissues by naturally occurring indoles of cruciferous plants. J. Natl. Cancer Inst. 1975; 54(4): 985-8.
16. Sepkovic D.W., Bradlow H.L. Estrogen hydroxylation – the good and the bad. Ann. N.Y. Acad. Sci. 2009; 1155: 57-67.
17. Szaefer H., Licznerska B., Krajka-Kuźniak V., Bartoszek A., Baer-Dubowska W. Modulation of CYP1A1, CYP1A2 and CYP1B1 expression by cabbage juices and indoles in human breast cell lines. Nutr. Cancer. 2012; 64(6):879-88.
18. Lord R.S., Bongiovanni B., Bralley J.A. Estrogen metabolism and the diet-cancer connection: rationale for assessing the ratio of urinary hydroxylated estrogen metabolites. Altern. Med. Rev. 2002; 7(2): 112-29.
19. Liu X., Lv K. Cruciferous vegetables intake is inversely associated with risk of breast cancer: a meta-analysis. Breast. 2013; 22(3): 309-13.
20. Weaver Z., Montagna C., Xu X., Howard T., Gadina M., Brodie S.G. et al. Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene. 2002; 21(33): 5097-107.
21. Crowe D.L., Lee M.K. New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. Breast Cancer Res. 2006; 8: R1.
22. Scully R. Role of BRCA gene dysfunction in breast and ovarian cancer predisposition. Breast Cancer Res. 2000; 2(5): 324-30.
23. Fan S., Wang J., Yuan R., Ma Y., Meng Q., Erdos M.R. et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science. 1999; 284(5418): 1354-6.
24. Knudson A.G. Mutation and cancer: Statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA. 1971; 68(4): 820-3.
25. Zheng L., Annab L.A., Afshari C.A., Lee W.H., Boyer T.G. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. Proc. Natl. Acad. Sci. 2001; 98(17): 9587-92.
26. Jones L.P., Li M., Halama E.D., Ma Y., Lubet R., Grubbs C.J. et al. Promotion of mammary cancer development by tamoxifen in a mouse model of BRCA1-mutation related breast cancer. Oncogene. 2005; 24(22): 3554-62.
27. Meng Q., Qi M., Chen D.Z., Yuan R., Goldberg I.D., Rosen E.M. et al. Supression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. J. Mol. Med. 2000; 78(3): 155-65.
28. Kotsopoulos J., Zhang S., Akbari M., Salmena L., Llacuachaqui M., Zeligs M. et al. BRCA1 mRNA levels following a 4–6-week intervention with oral 3,3’-diindolylmethane. Br. J. Cancer. 2014; 111(7): 1269-74.
29. Coupier I., Baldeyron C., Rousseau A., Mosseri V., Pages-Berhouet S., Caux-Moncoutier V. et al. Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations. Oncogene. 2004; 23(4): 914-9.
30. Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L., Bjeldanes L.F. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr. Cancer. 2004; 50(2): 161-7.
31. Zeligs M.A., Brownstone P.K., Sharp M.E., Westerlind K.S., Wilson S.M., Johs S.M. Managing cyclical mastalgia with absorbable diindolylmethane:a randomized, placebo-controlled trial. J. Am. Nutr. Assoc. 2005; 8(1): 5-15.
32. Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol. Biomarkers Prev. 2006; 15(6): 1229-31.
33. Meng Q., Yuan F., Goldberg I.D., Rosen E.M., Auborn K., Fan S. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J. Nutr. 2000; 130(12):2927-31.
34. Chernichenko I.I., Kulakova Yu.A. Alternative therapy of benign breast disease in women of reproductive and peri- and postmenopausal ages. In: Proceedings of the X Anniversary International Congress on Reproductive Medicine (January 19-22, 2016, Moscow). Moscow; 2016: 137-9. (in Russian)
35. Bradlow H.L., Zeligs M.A. Diindolylmethane (DIM) spontaneously forms from indole-3-carbinol (I3C) during cell culture experiments. In Vivo. 2010; 24(4): 387-91.
Received 16.12.2016
Accepted 23.12.2016
About the Authors
Smetnik Antonina Alexandrovna, PhD, a senior researcher at the Department of Gynecological Endocrinology, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74955314444, ext. 1543. E-mail: a_smetnik@oparina4.ruSmetnik Vera Petrovna, MD, Professor, Chief Researcher at the Department of Gynecological Endocrinology, Research Center of Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +74955314444, ext. 1543. E-mail: v_smetnik@oparina4.ru
Kiselev Vsevolod Ivanovich, Doctor of Biological Sciences, professor, corresponding member of Russian Academy of Sciences, Deputy Director of Institute of Biomedical Problems, Peoples’ Friendship University of Russia. 117198, Russia, Moscow, Miklukho-Maklaya str. 6. Tel.: +79857763116. E-mail: vkis10@mail.ru
For citations: Smetnik A.A., Smetnik V.P., Kiselev V.I. Experience with indole-3-carbinol used to treat diseases of the breast and to prevent breast cancer. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2017; (2): 106-12. (in Russian)
http://dx.doi.org/10.18565/aig.2017.2.106-12
Similar Articles
